VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Scagliotti Discusses the Future of Lung Cancer Therapy

Giorgio V. Scagliotti, MD, PhD
Published: Thursday, Sep 08, 2011



Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, believes that making a molecular diagnosis in solid tumors will become readily available in the future, not only in academic centers but also in the community setting. Molecular information will become critical in order to tailor systemic therapies to solid tumors, similar to how it is already being used in the field of hematologic malignancies.


Giorgio V. Scagliotti, MD, PhD, head of the Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, believes that making a molecular diagnosis in solid tumors will become readily available in the future, not only in academic centers but also in the community setting. Molecular information will become critical in order to tailor systemic therapies to solid tumors, similar to how it is already being used in the field of hematologic malignancies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x